Open Label Trial of Utility of Cryobiopsy in the Multidisciplinary Diagnosis of Idiopathic Interstitial Lung Disease
NCT ID: NCT02563730
Last Updated: 2016-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lung biopsy
assess the additional diagnostic value of cryobiopsy in patients with suspected Idiopathic Interstitial Pneumonia (IIP). Cryoprobe vs VATS
Lung biopsy
transbronchial lung biopsy. First kryobiopsy, second open biopsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lung biopsy
transbronchial lung biopsy. First kryobiopsy, second open biopsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* FVC\< 55%, DCO\<35%
* Platelet count \<100000/µl
* acetylsalicylic acid, clopidogrel or equivalent during the last 5 days
* INR \> l,3,
* elevated PTT (\> 40 s)
* documented pulmonary hypertension PAPS \>50mmHg
* HR-CT highly suspicious for sarcoidosis
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Boeckeler, Michael
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ruhrlandklinik
Essen, , Germany
Thoraxklinik
Heidelberg, , Germany
University Hospital Tuebingen
Tübingen, , Germany
Ospedale G.B. Morgagni
Forlì, , Italy
Respiratory Department Hospital of Santa Creu i Sant Pau
Barcelona, , Spain
Royal Brompton Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ulrich Costabel
Role: primary
Kaid Darwiche
Role: backup
Michael Kreuter, PD
Role: primary
Juergen Hetzel, MD
Role: primary
Poletti, Prof.
Role: primary
Alfons Torrego
Role: primary
Athol Wells
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRYO-VATS
Identifier Type: -
Identifier Source: org_study_id